arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Arcutis Biotherapeutics, Inc.

ARQT
$25.27 ▼ -1.15 (-4.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcutis Biotherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.2B
Dividend Yield
Revenue Growth 91.3%
Op. Margin -3.3%
ROIC -3.2%
FCF / Share $-0.05
Trailing P/E
Price / Book 16.5x
FCF Yield
Debt / Equity 0.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$376.07M
↑ +91.3%
Net Income Profit after all expenses
$-16.14M
↑ +88.5%
Operating Margin Operating profit as % of sales
-3.3%
↑ +95.0% 22th
FCF / Share Free cash flow per share
$-0.05
↑ +94.7%
Long-Term Debt Long-term obligations
$108.96M
↑ +1.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
22
Returns
35
Financial Health
45
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters